Our Founder
Dr. Chartier has been leading Research and Development projects for the Biotech industry for 20+ years, occupying positions of increasing responsibilities at large (Schering AG), medium (Iovance Biotherapeutics), and start-up (OncoMed Pharmaceuticals & NextVivo) size companies at preclinical and clinical stage and focusing on an array of human diseases including cystic fibrosis, multiple sclerosis, and cancer.
As VP of Research at Iovance Biotherapeutics, Dr. Chartier headed the Research and Translational Research departments. She oversaw the nonclinical development of next generation T cell therapies, including IOV-2001, a PBL-derived product for the treatment of CLL, LN-145-S1, a PD1-selected TIL product for the treatment of melanoma and HNSCC, and IOV-4001, a PD1-inactivated TIL product for the treatment of multiple solid tumor types.
At OncoMed Pharmaceuticals, Dr. Chartier directed Target Validation activities and led the project teams that brought multiple antibody therapeutics against cancer stem cells and immune checkpoints to the clinic, including anti-FZD vantictumab, anti-RSPO3 rosmantuzumab, and anti-TIGIT etigilimab.
Dr. Chartier’s early focus was on gene therapy, for which she invented the homologous recombination-based method used to manipulate adenoviral vectors that she worked with at both Schering (US Berlex) and Transgène (France) to deliver therapeutic genes such as CFTR, IFN-beta, and VEGFR.
In her most recent position as CSO of NextVivo, Dr. Chartier built the Research team and implemented an immune organoid technology platform for drug development.
Dr. Chartier obtained her PhD in Molecular Biology from the Université Louis Pasteur de Strasbourg, France, and pursued a post-doctoral training at Harvard Medical School.